Id: acc3275
Group: 2sens
Protein: CK2alpha
Gene Symbol: CSNK2A1
Protein Id: P68400
Protein Name: CSK21_HUMAN
PTM: phosphorylation
Site: Thr360
Site Sequence: MMSGISSVPTPSPLGPLAGSP
Disease Category: Nervous system diseases
Disease: Alzheimer's Disease
Disease Subtype:
Disease Cellline: N2aSwe?
Disease Info:
Drug: Cilostazol + resveratrol
Drug Info: "Cilostazol is a medication used to treat intermittent claudication by improving blood flow. | Resveratrol is a natural compound with potential health benefits, including antioxidant and anti - inflammatory properties. "
Effect: modulate
Effect Info: "Cilostazol enhances the phosphorylation and kinase activity of CK2α, provides upstream support for SIRT1 activation, and ultimately improves tauopathy."
Note:
Score: 4.0
Pubmed(PMID): 24254769
Sentence Index:
Sentence:

Sequence & Structure:

MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPTPSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 2 Completed COVID-19 ClinicalTrials
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 2 Terminated COVID-19 ClinicalTrials
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 1 Unknown status multiple myeloma ClinicalTrials
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 1 Suspended medulloblastoma ClinicalTrials
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 1 Active, not recruiting basal cell carcinoma ClinicalTrials
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 1 Completed cholangiocarcinoma ClinicalTrials
CSNK2A1 SILMITASERTIB Casein kinase II alpha inhibitor 1 Completed COVID-19 ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CSNK2A1-Ser194
Cancer Intensity
BRCA 1.752
COAD
HGSC
ccRCC 0.133
GBM -0.035
HNSC
LUAD 0.495
LUSC -0.289
non_ccRCC -1.672
PDAC 0.405
UCEC -0.789
CSNK2A1-Ser287
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.707
GBM
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: